Membrane metalloendopeptidase (MME) is positively correlated with systemic lupus erythematosus and may inhibit the occurrence of breast cancer.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
19
12
2022
accepted:
21
07
2023
medline:
18
8
2023
pubmed:
16
8
2023
entrez:
16
8
2023
Statut:
epublish
Résumé
Patients with systemic lupus erythematosus (SLE) have a lower risk of breast cancer (BRCA) than the general population. In this study, we explored the underlying molecular mechanism that is dysregulated in both diseases. Weighted gene coexpression network analysis (WGCNA) was executed with the SLE and BRCA datasets from the Gene Expression Omnibus (GEO) website and identified the potential role of membrane metalloendopeptidase (MME) in both diseases. Then, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses of related proteins and miRNAs were performed to investigate the potential molecular pathways. WGCNA revealed that MME was positively related to SLE but negatively related to BRCA. In BRCA, MME expression was significantly decreased in tumor tissues, especially in luminal B and infiltrating ductal carcinoma subtypes. Receiver operating characteristic (ROC) analysis identified MME as a valuable diagnostic biomarker of BRCA, with an area under the curve (AUC) value equal to 0.984 (95% confidence interval = 0.976-0.992). KEGG enrichment analysis suggested that MME-related proteins and targeted miRNAs may reduce the incidence of BRCA in SLE patients via the PI3K/AKT/FOXO signaling pathway. Low MME expression was associated with favorable relapse-free survival (RFS) but no other clinical outcomes and may contribute to resistance to chemotherapy in BRCA, with an AUC equal to 0.527 (P value < 0.05). In summary, MME expression was significantly decreased in BRCA but positively correlated with SLE, and it might reduce the incidence of BRCA in SLE patients via the PI3K/AKT/FOXO signaling pathway.
Sections du résumé
BACKGROUND
Patients with systemic lupus erythematosus (SLE) have a lower risk of breast cancer (BRCA) than the general population. In this study, we explored the underlying molecular mechanism that is dysregulated in both diseases.
METHODS
Weighted gene coexpression network analysis (WGCNA) was executed with the SLE and BRCA datasets from the Gene Expression Omnibus (GEO) website and identified the potential role of membrane metalloendopeptidase (MME) in both diseases. Then, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses of related proteins and miRNAs were performed to investigate the potential molecular pathways.
RESULTS
WGCNA revealed that MME was positively related to SLE but negatively related to BRCA. In BRCA, MME expression was significantly decreased in tumor tissues, especially in luminal B and infiltrating ductal carcinoma subtypes. Receiver operating characteristic (ROC) analysis identified MME as a valuable diagnostic biomarker of BRCA, with an area under the curve (AUC) value equal to 0.984 (95% confidence interval = 0.976-0.992). KEGG enrichment analysis suggested that MME-related proteins and targeted miRNAs may reduce the incidence of BRCA in SLE patients via the PI3K/AKT/FOXO signaling pathway. Low MME expression was associated with favorable relapse-free survival (RFS) but no other clinical outcomes and may contribute to resistance to chemotherapy in BRCA, with an AUC equal to 0.527 (P value < 0.05).
CONCLUSIONS
In summary, MME expression was significantly decreased in BRCA but positively correlated with SLE, and it might reduce the incidence of BRCA in SLE patients via the PI3K/AKT/FOXO signaling pathway.
Identifiants
pubmed: 37585411
doi: 10.1371/journal.pone.0289960
pii: PONE-D-22-34693
pmc: PMC10431625
doi:
Substances chimiques
MicroRNAs
0
Neprilysin
EC 3.4.24.11
Phosphatidylinositol 3-Kinases
EC 2.7.1.-
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0289960Informations de copyright
Copyright: © 2023 Ding et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Nucleic Acids Res. 2015 Jan;43(Database issue):D447-52
pubmed: 25352553
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Trends Biochem Sci. 2015 May;40(5):248-56
pubmed: 25818326
Semin Arthritis Rheum. 2021 Dec;51(6):1230-1241
pubmed: 34710720
Lupus. 2013 Aug;22(9):919-27
pubmed: 23857987
Semin Cancer Biol. 2018 Jun;50:21-31
pubmed: 29427645
Eur Rev Med Pharmacol Sci. 2019 Oct;23(20):8870-8877
pubmed: 31696489
Nucleic Acids Res. 2018 Jan 4;46(D1):D380-D386
pubmed: 29087512
Nucleic Acids Res. 2019 Jul 2;47(W1):W561-W565
pubmed: 31114869
Nat Commun. 2019 Dec 12;10(1):5679
pubmed: 31831737
Ann Med. 2021 Dec;53(1):1019-1031
pubmed: 34187256
Int J Cancer. 2019 Dec 1;145(11):3140-3151
pubmed: 31020993
Neurol Genet. 2016 Aug 18;2(5):e94
pubmed: 27583304
Expert Rev Clin Immunol. 2018 Oct;14(10):793-802
pubmed: 30183456
Nucleic Acids Res. 2015 Jul 1;43(W1):W460-6
pubmed: 25977294
Tumour Biol. 2016 Oct;37(10):13355-13368
pubmed: 27460083
Cancer Cell. 2021 Oct 11;39(10):1361-1374.e9
pubmed: 34478639
Am J Pathol. 2019 Jul;189(7):1462-1472
pubmed: 31054987
Comput Methods Programs Biomed. 2013 Oct;112(1):135-45
pubmed: 23871682
Nat Chem Biol. 2016 Feb;12(2):109-16
pubmed: 26656090
Semin Cancer Biol. 2021 Jul;72:46-64
pubmed: 32497683
Arthritis Res Ther. 2021 Feb 25;23(1):64
pubmed: 33632283
Br J Radiol. 2022 Feb 1;95(1130):20211033
pubmed: 34905391
Autophagy. 2019 Feb;15(2):312-326
pubmed: 30289335
Int J Mol Sci. 2020 Dec 26;22(1):
pubmed: 33375317
Nucleic Acids Res. 2020 Jul 2;48(W1):W244-W251
pubmed: 32484539
Ann Rheum Dis. 2021 Jan;80(1):14-25
pubmed: 33051219
Bioinformatics. 2016 Sep 15;32(18):2847-9
pubmed: 27207943
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Mol Cancer. 2020 Feb 4;19(1):22
pubmed: 32019587
Front Immunol. 2021 Jul 15;12:658341
pubmed: 34335565
Semin Cancer Biol. 2022 Feb;79:91-104
pubmed: 34280576
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Signal Transduct Target Ther. 2021 Dec 16;6(1):425
pubmed: 34916492
Semin Cancer Biol. 2022 May;80:1-17
pubmed: 31866476
Nat Rev Cancer. 2020 Aug;20(8):417-436
pubmed: 32528185
Oncogenesis. 2020 Mar 23;9(3):38
pubmed: 32205838
Nat Rev Cancer. 2020 Feb;20(2):74-88
pubmed: 31686003
J Med Internet Res. 2021 Jul 26;23(7):e27633
pubmed: 34309564
Nucleic Acids Res. 2021 Jul 2;49(W1):W317-W325
pubmed: 34086934